Free Trial
ASX:CUV

Clinuvel Pharmaceuticals (CUV) Stock Price, News & Analysis

Clinuvel Pharmaceuticals logo

About Clinuvel Pharmaceuticals Stock (ASX:CUV)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
124,193 shs
Average Volume
N/A
Market Capitalization
$563.18 million
P/E Ratio
15.95
Dividend Yield
0.44%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Receive CUV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clinuvel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CUV Stock News Headlines

Clinuvel Pharmaceuticals Stock Price History
Trump: "Buy Stocks Now!" (Here's a Better Move)
Trump: "Buy Stocks Now!" (Here's a Better Move) President Trump just announced from the Oval Office: "You better go out and buy stocks now. The market will take off like a rocket ship." And he's absolutely right—stocks like Apple, Tesla, and Nvidia are soaring... But here's something most investors are missing: You can turn this historic surge into immediate monthly income—potentially up to $5,917! No more waiting years for stock prices to rise...
High Growth Tech Stocks In Australia For March 2025
See More Headlines

CUV Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Clinuvel Pharmaceuticals investors own include Cochlear (COH), CSL (CSL), ResMed (RMD), ARB (ARB), Accent Group (AX1), Corporate Travel Management (CTD) and Mineral Resources (MIN).

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
ASX:CUV
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
15.95
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$35.64 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$88.18 million
Price / Cash Flow
19.36
Book Value
A$4.02 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$563.18 million
Optionable
Not Optionable
Beta
0.92
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (ASX:CUV) was last updated on 6/26/2025 by MarketBeat.com Staff
From Our Partners